Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Poised to Reach USD 1598 Million by 2033 at a 9.6% of CAGR Amid Rising Awareness and Advanced Treatment Options

Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market

The global market for warm autoimmune hemolytic anemia (WAIHA) treatment achieved a valuation of USD 582.99 million in 2022 and is projected to experience substantial growth, reaching an estimated USD 1,598 million by 2033. This growth trajectory represents a notable compound annual growth rate (CAGR) of 9.6% over the forecast period from 2023 to 2033, marking a significant acceleration compared to the historical CAGR of 5.4% between 2018 and 2022.

The rising prevalence of WAIHA globally has driven demand for effective treatments, while advancements in medical research have led to more precise diagnostic methods, improving diagnosis rates. Furthermore, increasing awareness among healthcare professionals and patients is contributing to higher treatment adoption rates, further fueling market growth.

Innovations in treatment methods are also a key driver of market expansion. With new therapies on the horizon that offer greater efficacy and fewer side effects, the WAIHA treatment landscape is evolving, providing patients with improved quality of life and better health outcomes. Pharmaceutical companies and research institutions are actively engaged in developing advanced therapeutic solutions, which is expected to enhance patient outcomes and provide a significant boost to market dynamics.

In certain cases, there could be blood transfusions used for replacing blood cells that have been destroyed. In case of severity, a splenectomy (removing the spleen surgically) could be essential for reducing red blood cells’ destruction.

The pharmaceuticals vertical is into adoption of novel treatments for the autoimmune diseases inclusive of WAIHA. On these grounds, the US FDA, in 2019, did approve Zilucoplan (brand name: Viltepso) to treat autoimmune hemolytic anemia.

At the same time, the fact that WAIHA treatments are costly can’t be ignored; especially for the ones who need prolonged therapy. This could make it tad difficult for certain patients to continue. Furthermore, the downtime needed on the whole is also more as diagnosis for WAIHA is made by combining laboratory tests, clinical evaluation, and imaging studies; which could be resulting in delays in treatment. These factors are likely to restrain the Warm Autoimmune Hemolytic Anemia (WAIHA) treatment market shortly.

Key Takeaways from Global Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry:

• North America holds the largest market share due to the US being subject to advanced healthcare infrastructure along with an influx of skilled workforce.
• Europe holds the second-largest market share with growing advancements in healthcare vertical with novel diagnostic tools as well as treatment options.
• The Asia-Pacific is expected to grow at the quickest rate in the warm autoimmune hemolytic anemia (WAIHA) treatment market with growing awareness regarding diagnosis of WAIHA.

What are the Challenges Faced by the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market?

Lack of specific diagnostic tests and limited understanding of the disease derailing market growth

There is currently no single diagnostic test that can confirm a diagnosis of WAIHA. The diagnosis is often made through a combination of clinical evaluation, laboratory tests, and imaging studies, which can lead to delays in diagnosis and treatment.

Despite advances in medical research, the exact causes of WAIHA are not yet fully understood. This limited understanding makes it difficult to develop targeted treatments for the disease. There are currently limited treatment options available for WAIHA, and existing treatments such as corticosteroids can have significant side effects. This can make it challenging for patients to find effective treatment options.

The cost of treating WAIHA can be high, especially for patients who require long-term therapy. This can make it difficult for some patients to access the treatment they need. Treatment for WAIHA often involves a combination of drugs and therapies that need to be taken over a long period of time. This can be challenging for some patients, and may impact the effectiveness of the treatment.

Market Competition

Key players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Sanofi, Incyte Corporation, Teva Pharmaceutical Industries Ltd, Momenta Pharmaceuticals, Alexion Pharmaceuticals, Inc., Immunovant, F. Hoffmann-La Roche Ltd

• Rigel Pharmaceuticals has been working on the development of a drug called Fostamatinib (also known as Tavalisse) for the treatment of Warm Autoimmune Hemolytic Anemia (WAIHA). Fostamatinib is an oral drug that inhibits spleen tyrosine kinase (SYK), an enzyme that is involved in immune cell signaling. In WAIHA, autoantibodies attack and destroy red blood cells, leading to anemia. By inhibiting SYK, Fostamatinib is designed to reduce the destruction of red blood cells and improve anemia in patients with WAIHA.

Key Companies Profiled

• Rigel Pharmaceuticals
• Apellis Pharmaceuticals, Inc.
• Sanofi
• Incyte Corporation
• Teva Pharmaceutical Industries Ltd
• Momenta Pharmaceuticals
• Alexion Pharmaceuticals, Inc.
• Immunovant
• F. Hoffmann-La Roche Ltd

A Full Report Overview

Key Segments Profiled in the Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Industry Survey

Drug Class:

• Fostamatinib
• Sutimlimab
• Parsaclisib
• Rilzabrutinib
• Isatuximab

Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube